Literature DB >> 21743209

Prognosis of HTLV-1 positive renal transplant recipients in Iran.

Orode Naghibi1, Fatemeh Nazemian, Massih Naghibi, D B Ali Javidi.   

Abstract

The human T lymphocyte virus-1 (HTLV-1) is the responsible pathogen for diseases such as HTLV-1 associated myelopathy (HAM) and adult T-cell leukemia (ATL). Mashhad, in northeast Iran, with high instances of this infection, has a noticeable number of infected renal failure patients. Since immunosuppressive drugs might decrease the latency period of HTLV-1 or increase its complications, the question arises whether HTLV-1 positive renal failure patients are suitable candidates for kidney transplants. To answer this, HTLV-1 positive recipients were evaluated in our study. Patients were divided into two groups. First group consisted of patients at the Imam Reza Hospital dialysis center. Second group had 20 kidney transplantation recipients consisting of ten infected and ten uninfected recipients as control from Imam Reza. Medical history of these patients was recorded and evaluated. The follow-up periods were between one and six years. Among them, 3.8% of patients undergoing dialysis were infected. The most important fact resulting from this study is that none of the infected recipients suffered from HAM or ATL during the follow-up period. In addition, it did not show any significant difference in the incidence of post-transplant complications between the infected and non-infected groups. Our study indicates that HTLV-1 positive patients may undergo kidney transplant without fear of increased incidence of side effects than those found in uninfected recipients. Because of short-term follow-up, probable long latency period of the virus, and the limited number of infected recipients, further work on this issue would be prudent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21743209

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  5 in total

1.  HTLV-1-associated myelopathy in a solid organ transplant recipient.

Authors:  Maria Jose Montesdeoca Andrade; Edgar Patricio Correa Diaz; Maria Eugenia Buestán
Journal:  BMJ Case Rep       Date:  2016-06-06

2.  Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis.

Authors:  Fabiola Martin; Hannah Castro; Carolyn Gabriel; Adine Adonis; Alexandra Fedina; Linda Harrison; Liz Brodnicki; Maria A Demontis; Abdel G Babiker; Jonathan N Weber; Charles R M Bangham; Graham P Taylor
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

3.  Oncogenic Virus Infections in the General Population and End-stage Renal Disease Patients With Special Emphasis on Kaposi's Sarcoma Associated Herpes Virus (KSHV) in Northeast of Iran.

Authors:  Sanaz Ahmadi Ghezeldasht; Tahereh Hassannia; Houshang Rafatpanah; Reza Hekmat; Narges Valizadeh; Majid Ghayour Mobarhan; Seyed Abdolrahim Rezaee
Journal:  Jundishapur J Microbiol       Date:  2015-03-21       Impact factor: 0.747

Review 4.  Rare and emerging viral infections in transplant recipients.

Authors:  Jesse J Waggoner; Elizabeth A Soda; Stan Deresinski
Journal:  Clin Infect Dis       Date:  2013-07-09       Impact factor: 9.079

Review 5.  p30 protein: a critical regulator of HTLV-1 viral latency and host immunity.

Authors:  Ramona Moles; Sarkis Sarkis; Veronica Galli; Maria Omsland; Damian F J Purcell; David Yurick; Georges Khoury; Cynthia A Pise-Masison; Genoveffa Franchini
Journal:  Retrovirology       Date:  2019-12-18       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.